# A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

> **NCT07089992** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 32 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07089992
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-04
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07089992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07089992, "A Study of Pembrolizumab in People With Ultra-Rare Sarcomas". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT07089992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*